公开(公告)号：US20200254024A1

公开(公告)日：2020-08-13

申请号：US16633618

申请日：2018-06-21

Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Sung Won KIM ,  Seung Ki KWOK ,  Jaeseon LEE ,  Sun hwa PARK ,  Jung Yeon Lim

IPC: A61K35/28 ,  A61P19/02

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating rheumatoid arthritis, and a stem cell therapeutic agent for treating rheumatoid arthritis, comprising nasal inferior turbinate-derived mesenchymal stem cells as an active ingredient. Nasal inferior turbinate-derived mesenchymal stem cells of the present invention have the effects of reducing the production of interleukin-17A (IL-17A), tumor necrosis factor-α (TNF-α), immunoglobulin G2 (IgG2a) which is an inflammation-inducing factor, and/or the proliferative ability of lymph node T cells, increasing interleukin-10 (IL-10) and/or regulatory T-cells (Treg, CD4+CD25+foxp3+ cell) that contribute to immune tolerance in spleen cells, and inhibiting the proliferation of human T-cells. The nasal inferior turbinate-derived mesenchymal stem cells have a safer acquisition process than existing mesenchymal stem cells and can be acquired in sufficient amounts within a desired period of time, thus allowing mesenchymal stem cells to be acquired at low cost and high efficiency. Moreover, since the nasal inferior turbinate-derived mesenchymal stem cells have the same genetic origin as individuals administered therewith there are few side effects, the nasal inferior turbinate-derived mesenchymal stem cells can be usefully used for preventing or treating in individually tailored immunocompatible rheumatoid arthritis.

公开(公告)号：US20170239295A1

公开(公告)日：2017-08-24

申请号：US13966153

申请日：2013-08-13

Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Mi La Cho ,  Seok-Goo Cho ,  Jung-Yeon Lim ,  Hyun-Sil Park ,  Min-Jung Park

IPC: A61K35/28 ,  C12N5/0775 ,  C12N5/0783 ,  A61K35/17

Abstract: The present invention relates to a cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory T-cells as an active ingredient. By infusing mesenchymal stem cells and immunoregulatory T-cells, which are the cellular therapeutic agent of the present invention, into bone marrow transplant animals, rejection to the host is suppressed after the engraftment of the transplanted bone-marrow to thus obtain the effect of reducing graft-versus-host disease and immune disease. Moreover, the effect of such GVHD reduction is much greater than the one obtained when only mesenchymal stem cells are infused. Accordingly, the cell therapy composition of the present invention having the above-mentioned effects can be useful in the prevention or treatment of immune disease.

公开(公告)号：US20170204463A1

公开(公告)日：2017-07-20

申请号：US15307555

申请日：2014-09-30

Applicant: Catholic University Industry Academic Cooperation Foundation

Inventor： Yeun-Jun CHUNG ,  Tae-Hwan KIM ,  Seung Cheol SHIM ,  Seung-Hyun JUNG

IPC: C12Q1/68

CPC classification number: C12Q1/6883 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/158

Abstract: The present invention relates to a method of predicting the risk of developing ankylosing spondylitis using DNA copy number variation. It was verified that the risk of developing ankylosing spondylitis can be effectively predicted using primers for detecting DNA copy number variation, of the present invention, and the sensitivity and specificity of prediction can be improved by grafting the results of single nucleotide polymorphism (SNP) measurements, and thus more fundamental approaches for preventing and treating ankylosing spondylitis are expected.

公开(公告)号：US09700531B2

公开(公告)日：2017-07-11

申请号：US14663235

申请日：2015-03-19

Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Mi-La Cho ,  Seon-Yeong Lee ,  Eun-Ji Yang ,  Hye-Jin Son ,  Eun-Kyung Kim ,  Jun-Geol Ryu

IPC: A61K31/155 ,  A61K38/17 ,  A61K39/395 ,  A61P37/02 ,  A61K45/06

CPC classification number: A61K31/155 ,  A61K38/1793 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to a composition comprising metformin as an active ingredient for preventing or treating inflammatory bowel disease. The metformin compound or the metformin-etanercept (product name: Enbrel) composite according to the present invention may have excellent effects of maintaining the thickness of the small intestine and length of the large intestine normal, inhibiting or decreasing the activity of IL-17 and TNF-a, and promoting or increasing the activity of IFNr, and therefore can be effectively used as a pharmaceutical composition for preventing or treating autoimmune diseases including inflammatory bowel disease.

公开(公告)号：US20160058283A1

公开(公告)日：2016-03-03

申请号：US14781903

申请日：2013-12-10

Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Choun-ki Joo

IPC: A61B3/117 ,  A61B3/00 ,  A61B3/14 ,  A61B3/10

CPC classification number: A61B3/1173 ,  A61B3/0025 ,  A61B3/102 ,  A61B3/14 ,  G01B9/0203 ,  G01B9/02091

Abstract: A method for calculating the center of the anterior capsule includes the steps of: photographing the eyeball of a patient with an optical coherence tomography; generating a 3-dimensional image and coordinates based on the data obtained by the optical coherence tomography; photographing the eyeball of the patient to produce an eyeball image; and matching the 3-dimensional image and coordinates to the eyeball image so as to calculate the center of the anterior capsule of the patient. A system for calculating the center of the anterior capsule includes: an optical coherence tomography apparatus for photographing the eyeball of a patient with an optical coherence tomography; a photographing device for photographing the eyeball of the patient to generate an eyeball image; and a central processing unit for generating a 3-dimensional image and coordinates based on the data obtained by the optical coherence tomography apparatus to match the 3-dimensional image and coordinates to the eyeball image obtained by the photographing device so as to calculate the center of the anterior capsule of the patient.

Abstract translation: 用于计算前囊的中心的方法包括以下步骤：用光学相干断层摄影术拍摄患者的眼球; 基于通过光学相干断层摄影获得的数据生成三维图像和坐标; 拍摄患者的眼球以产生眼球图像; 并将三维图像和坐标与眼球图像相匹配，以便计算患者前囊的中心。 用于计算前囊的中心的系统包括：光学相干断层摄影装置，用于用光学相干断层摄影术拍摄患者的眼球; 用于拍摄患者的眼球以产生眼球图像的拍摄装置; 以及中央处理单元，用于基于由所述光学相干断层摄影装置获得的数据生成三维图像并进行坐标，以将所述三维图像和坐标与由所述拍摄装置获得的眼球图像相匹配，以计算所述三维图像的中心 患者的前囊。

公开(公告)号：US09262691B2

公开(公告)日：2016-02-16

申请号：US14262636

申请日：2014-04-25

Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Hang-Bong Kang ,  Sang-Hyun Cho

IPC: G06K9/00 ,  G06K9/34 ,  G06T15/00 ,  G06K9/46 ,  G06K9/62 ,  G06T7/00

CPC classification number: G06K9/4676 ,  G06K9/6202 ,  G06T7/11 ,  G06T2207/10012 ,  G06T2207/10024

Abstract: The method for extracting salient object from stereoscopic video includes: dividing regions based on the similarity of color and the distance between pixels in a left-eye image and a right-eye image which are used for an input stereoscopic image; creating a disparity map based on a disparity obtained from a pixel difference of the left-eye image and the right-eye image; calculating a contrast-based saliency by comparing the divided regions and the divided regions of the disparity map; calculating a prior-knowledge-based saliency based on a prior-knowledge for the divided regions and the divided regions of the disparity map; and extracting salient regions of the image based on the contrast-based saliency and the prior-knowledge-based saliency.

Abstract translation: 用于从立体视频中提取突出物体的方法包括：基于颜色的相似度和用于输入立体图像的左眼图像和右眼图像中的像素之间的距离来划分区域; 基于从左眼图像和右眼图像的像素差获得的视差来创建视差图; 通过比较视差图的分割区域和分割区域来计算基于对比度的显着性; 基于视差图的分割区域和分割区域的先验知识计算基于知识的先验显着性; 并基于基于对比度的显着性和先验知识的显着性来提取图像的突出区域。

公开(公告)号：US20150238445A1

公开(公告)日：2015-08-27

申请号：US14428920

申请日：2013-09-06

Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION

Inventor： Mi-La Cho ,  Seon-Yeong Lee ,  Min-Jung Park ,  Jae-Seon Lee ,  Eun-Ji Yang ,  Eun-Kyung Kim ,  Jun-Geol Ryu ,  Hye-Jin Son

IPC: A61K31/155

CPC classification number: A61K31/155

Abstract: The present invention relates to a composition for preventing or treating immune diseases through the suppression of B cell activity induced by metformin. More particularly, the present invention relates to a composition comprising a metformin compound or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating immune diseases, wherein the composition is characterized by suppression or reduction of B cell activity which is a cause of disease. The present invention can be valuable in the use thereof for various autoimmune diseases as an immunosuppressant which can prevent or treat immune diseases by suppressing or reducing B cell activity and Th17 cell activity, which are causes of disease, or by promoting or increasing regulatory T cell activity.

Abstract translation: 本发明涉及通过抑制二甲双胍诱导的B细胞活性来预防或治疗免疫疾病的组合物。 更具体地，本发明涉及包含二甲双胍化合物或其药学上可接受的盐作为预防或治疗免疫疾病的活性成分的组合物，其中所述组合物的特征在于抑制或降低作为疾病原因的B细胞活性 。 本发明在各种自身免疫性疾病中作为免疫抑制剂的用途是有价值的，该免疫抑制剂可以通过抑制或降低作为疾病原因的B细胞活性和Th17细胞活性或通过促进或增加调节性T细胞来预防或治疗免疫疾病 活动。

公开(公告)号：US20150080245A1

公开(公告)日：2015-03-19

申请号：US14371792

申请日：2012-10-31

Applicant: CATHOLIC UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Ji-Hyeon Ju ,  Young-Kyun Kim

IPC: G01N33/564

CPC classification number: G01N33/564 ,  G01N2800/102

Abstract: The present invention aims to diagnose rheumatoid arthritis more accurately and rapidly, and relates to a method and a kit for diagnosing rheumatoid arthritis, based on the detection of citrullinated autoantigens in a test sample.

Abstract translation: 本发明旨在更准确，快速地诊断类风湿关节炎，并且涉及一种用于诊断类风湿性关节炎的方法和试剂盒，其基于检测样品中瓜氨酸化的自身抗体。

公开(公告)号：US20140296319A1

公开(公告)日：2014-10-02

申请号：US14122236

申请日：2012-05-24

Applicant: Catholic University Industry Academic Cooperation Foundation

Inventor： Suk Kyeong Lee ,  Hoyun Choi

IPC: C12N15/113 ,  A61K31/713

CPC classification number: C12N15/113 ,  A61K31/713 ,  A61K45/06 ,  C12N2310/141 ,  A61K2300/00

Abstract: Provided is a use of an miRNA of an Epstein-Barr virus (EBV), more specifically, EBV miR-BART4-5p, miR-BART4-3p, miR-BART1-5p, miR-BART15-3p, miR-BART5-5p, miR-BART5-3p, miR-BART16-5p, miR-BART16-3p, miR-BART17-3p, miR-BART21-3p, miR-BART18-5p, miR-BART7-5p, miR-BART9-5p, miR-BART22-5p, miR-BART20-3p, miR-BART13-5p, miR-BART13-3p, miR-BART2-3p, and mimics thereof for promoting apoptosis or inhibiting cell growth.

Abstract translation: 提供了EB病毒（EBV）的miRNA，更具体地，EBV miR-BART4-5p，miR-BART4-3p，miR-BART1-5p，miR-BART15-3p，miR-BART5-5p ，miR-BART5-3p，miR-BART16-5p，miR-BART16-3p，miR-BART17-3p，miR-BART21-3p，miR-BART18-5p，miR-BART7-5p，miR-BART9-5p，miR -BART22-5p，miR-BART20-3p，miR-BART13-5p，miR-BART13-3p，miR-BART2-3p及其模拟物，用于促进细胞凋亡或抑制细胞生长。

公开(公告)号：US08470558B1

公开(公告)日：2013-06-25

申请号：US13664465

申请日：2012-10-31

Applicant: Catholic University Industry-Academic Cooperation Foundation

Inventor： Hyang-Shuk Rhim ,  Goo-Young Kim ,  Jeong-Mi Moon

IPC: C12P21/06

CPC classification number: C07K14/52 ,  C07K14/4747 ,  C07K14/7151 ,  C07K2319/42 ,  C12P21/02

Abstract: The present invention relates to a technique for the T7 promoter-driven expression of a foreign protein, preferably, a human protein in E. coli having no T7 RNA polymerase. More particularly, the present invention relates to use of a vector including a T7 promoter and an N-terminal HA tag sequence for overexpression of a foreign protein in E. coli having no T7 RNA polymerase, E. coli that includes the vector and is able to overexpress the foreign protein in the absence of T7 RNA polymerase, a method for expressing or producing the foreign protein using the E. coli, and a method for analyzing functions of the foreign protein. Further, the present invention relates to a simple, rapid method for evaluating the expression and cytotoxicity of a human protein in E. coli by using the vector.

Abstract translation: 本发明涉及T7启动子驱动的外源蛋白质，优选人蛋白质在没有T7 RNA聚合酶的大肠杆菌中表达的技术。 更具体地，本发明涉及包含T7启动子和N末端HA标签序列的载体在不含T7RNA聚合酶的大肠杆菌中的外源蛋白质的过表达的使用，所述大肠杆菌包含载体并且能够 在不存在T7 RNA聚合酶的情况下过表达外源蛋白质，使用大肠杆菌表达或产生外源蛋白质的方法以及分析外源蛋白质的功能的方法。 此外，本发明涉及通过使用载体来评价人类蛋白质在大肠杆菌中的表达和细胞毒性的简单，快速的方法。